Low-intensity Shockwave Therapy for Non-bacterial Prostatitis/Pelvic Pain Syndrome
Launched by INSTITUTE FOR THE STUDY OF UROLOGICAL DISEASES, GREECE · May 20, 2018
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Participant must 18 to 60 years of age.
- • 2. Participant has signed and dated the appropriate Informed Consent document.
- • 3. Participant has had a clinical diagnosis of CP/CPPS defined as symptoms of discomfort or pain in the perineal or pelvic region for at least a three (3) month period within the last six (6) months
- Exclusion Criteria:
- • 1. Participant has evidence of facultative Gram negative or enterococcus with a value of ≥ 1000 CFU/ml in mid-stream urine (VB2).
- • 2. Participant has a history of prostate, bladder or urethral cancer.
- • 3. Participant has undergone pelvic radiation or systemic chemotherapy.
- • 4. Participant has undergone intravesical chemotherapy.
- • 5. Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition associated with LUTS, any neurological disease or disorder affecting the bladder.
- • 6. Participant has undergone prostate surgery or treatment.
- • 7. Participant with penile or urinary sphincter implants.
- • 8. Participant has been diagnosed with cancer during the last 5 years, or had any surgery in the pelvis.
- • 9. Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.
- • 10. PI-RADS score 4-5 in the baseline prostate mpMRI
- • 11. PI-RADS score 3, PSA\>3 and age \> 40 years
- • 12. Positive (suspicious for malignancy) DRE.
About Institute For The Study Of Urological Diseases, Greece
The Institute for the Study of Urological Diseases in Greece is a leading research organization dedicated to advancing the understanding and treatment of urological conditions. With a focus on innovative clinical trials, the Institute aims to improve patient outcomes through cutting-edge research and collaboration with healthcare professionals. By integrating clinical expertise and scientific inquiry, the Institute fosters an environment that promotes the development of novel therapies and enhances the overall quality of care for patients suffering from urological disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Thessaloniki, , Greece
Patients applied
Trial Officials
Dimitrios Hatzichristou, Prof.
Principal Investigator
Institute for the Study of Urological Diseases, Thessaloniki, Greece
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials